SE461703B - Farmaceutiskt preparat foer behandling av hypertension eller kongestiv hjaertaakomma bestaaende av n-cyano-n-4-pyridyl-n -1,2,2-trimetylpropylguanidin och ett diuretikum - Google Patents
Farmaceutiskt preparat foer behandling av hypertension eller kongestiv hjaertaakomma bestaaende av n-cyano-n-4-pyridyl-n -1,2,2-trimetylpropylguanidin och ett diuretikumInfo
- Publication number
- SE461703B SE461703B SE8202351A SE8202351A SE461703B SE 461703 B SE461703 B SE 461703B SE 8202351 A SE8202351 A SE 8202351A SE 8202351 A SE8202351 A SE 8202351A SE 461703 B SE461703 B SE 461703B
- Authority
- SE
- Sweden
- Prior art keywords
- diuretic
- hypertension
- treatment
- pyridyl
- cyano
- Prior art date
Links
- 206010020772 Hypertension Diseases 0.000 title claims description 8
- 238000011282 treatment Methods 0.000 title claims description 7
- 239000000825 pharmaceutical preparation Substances 0.000 title claims 2
- 239000003826 tablet Substances 0.000 claims description 20
- 239000002934 diuretic Substances 0.000 claims description 15
- 230000001882 diuretic effect Effects 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 13
- 229960003515 bendroflumethiazide Drugs 0.000 claims description 10
- HDWIHXWEUNVBIY-UHFFFAOYSA-N bendroflumethiazidum Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1NC2CC1=CC=CC=C1 HDWIHXWEUNVBIY-UHFFFAOYSA-N 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 7
- 231100000252 nontoxic Toxicity 0.000 claims description 6
- 230000003000 nontoxic effect Effects 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- MAEIEVLCKWDQJH-UHFFFAOYSA-N bumetanide Chemical compound CCCCNC1=CC(C(O)=O)=CC(S(N)(=O)=O)=C1OC1=CC=CC=C1 MAEIEVLCKWDQJH-UHFFFAOYSA-N 0.000 claims description 5
- 229960004064 bumetanide Drugs 0.000 claims description 5
- 229960003883 furosemide Drugs 0.000 claims description 5
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 239000000969 carrier Substances 0.000 claims description 4
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 229960003313 hydroflumethiazide Drugs 0.000 claims description 2
- DMDGGSIALPNSEE-UHFFFAOYSA-N hydroflumethiazide Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O DMDGGSIALPNSEE-UHFFFAOYSA-N 0.000 claims description 2
- 239000002171 loop diuretic Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 229940097420 Diuretic Drugs 0.000 claims 2
- 229940121792 Thiazide diuretic Drugs 0.000 claims 1
- 239000003451 thiazide diuretic agent Substances 0.000 claims 1
- 239000005458 thiazide-like diuretic Substances 0.000 claims 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 22
- 239000008187 granular material Substances 0.000 description 13
- 150000004682 monohydrates Chemical class 0.000 description 13
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 12
- 235000019359 magnesium stearate Nutrition 0.000 description 11
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 10
- 229960001375 lactose Drugs 0.000 description 10
- 239000008101 lactose Substances 0.000 description 10
- 239000007787 solid Substances 0.000 description 6
- 229940124549 vasodilator Drugs 0.000 description 6
- 239000003071 vasodilator agent Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- 229920002261 Corn starch Polymers 0.000 description 4
- 229920000609 methyl cellulose Polymers 0.000 description 4
- 239000001923 methylcellulose Substances 0.000 description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
- -1 pyretamide Chemical compound 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 2
- RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 235000019759 Maize starch Nutrition 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 229960004977 anhydrous lactose Drugs 0.000 description 2
- 230000003276 anti-hypertensive effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000001913 cellulose Chemical class 0.000 description 2
- 229920002678 cellulose Chemical class 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000008119 colloidal silica Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 229940075507 glyceryl monostearate Drugs 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- PRKWVSHZYDOZLP-UHFFFAOYSA-N 2-[(6,7-dichloro-2-methyl-1-oxo-2-phenyl-3h-inden-5-yl)oxy]acetic acid Chemical compound C1C2=CC(OCC(O)=O)=C(Cl)C(Cl)=C2C(=O)C1(C)C1=CC=CC=C1 PRKWVSHZYDOZLP-UHFFFAOYSA-N 0.000 description 1
- JIVPVXMEBJLZRO-CQSZACIVSA-N 2-chloro-5-[(1r)-1-hydroxy-3-oxo-2h-isoindol-1-yl]benzenesulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC([C@@]2(O)C3=CC=CC=C3C(=O)N2)=C1 JIVPVXMEBJLZRO-CQSZACIVSA-N 0.000 description 1
- ALKYHXVLJMQRLQ-UHFFFAOYSA-N 3-Hydroxy-2-naphthoate Chemical compound C1=CC=C2C=C(O)C(C(=O)O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- SMNOERSLNYGGOU-UHFFFAOYSA-N Mefruside Chemical compound C=1C=C(Cl)C(S(N)(=O)=O)=CC=1S(=O)(=O)N(C)CC1(C)CCCO1 SMNOERSLNYGGOU-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 1
- 229920000881 Modified starch Chemical class 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- CYLWJCABXYDINA-UHFFFAOYSA-N Polythiazide Polymers ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)N(C)C(CSCC(F)(F)F)NC2=C1 CYLWJCABXYDINA-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Chemical class 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 229960002155 chlorothiazide Drugs 0.000 description 1
- 229960001523 chlortalidone Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 238000011340 continuous therapy Methods 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 229960003176 cyclothiazide Drugs 0.000 description 1
- BOCUKUHCLICSIY-QJWLJZLASA-N cyclothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1NC2C1[C@H](C=C2)C[C@H]2C1 BOCUKUHCLICSIY-QJWLJZLASA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- AVOLMBLBETYQHX-UHFFFAOYSA-N etacrynic acid Chemical compound CCC(=C)C(=O)C1=CC=C(OCC(O)=O)C(Cl)=C1Cl AVOLMBLBETYQHX-UHFFFAOYSA-N 0.000 description 1
- 229960003199 etacrynic acid Drugs 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- VZVGEDRCVUKSEL-UHFFFAOYSA-N guancidine Chemical compound CCC(C)(C)N=C(N)NC#N VZVGEDRCVUKSEL-UHFFFAOYSA-N 0.000 description 1
- 229950007639 guancidine Drugs 0.000 description 1
- 229960002474 hydralazine Drugs 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- 229950009607 indacrinone Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 229960004678 mefruside Drugs 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 229960003632 minoxidil Drugs 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229960005483 polythiazide Drugs 0.000 description 1
- 229920000046 polythiazide Polymers 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000008107 starch Chemical class 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229940124591 thiazide-type diuretic Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 229960004813 trichlormethiazide Drugs 0.000 description 1
- LMJSLTNSBFUCMU-UHFFFAOYSA-N trichlormethiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC(C(Cl)Cl)NS2(=O)=O LMJSLTNSBFUCMU-UHFFFAOYSA-N 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB8111986 | 1981-04-15 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SE8202351L SE8202351L (sv) | 1982-10-16 |
| SE461703B true SE461703B (sv) | 1990-03-19 |
Family
ID=10521198
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE8202351A SE461703B (sv) | 1981-04-15 | 1982-04-14 | Farmaceutiskt preparat foer behandling av hypertension eller kongestiv hjaertaakomma bestaaende av n-cyano-n-4-pyridyl-n -1,2,2-trimetylpropylguanidin och ett diuretikum |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US4409222A (pt) |
| JP (1) | JPS57197219A (pt) |
| AU (1) | AU550569B2 (pt) |
| BE (1) | BE892873A (pt) |
| CA (1) | CA1172566A (pt) |
| DE (1) | DE3213579A1 (pt) |
| FR (1) | FR2504008B1 (pt) |
| GB (1) | GB2098864B (pt) |
| IE (1) | IE52935B1 (pt) |
| IT (1) | IT1152106B (pt) |
| NL (1) | NL8201493A (pt) |
| NZ (1) | NZ200185A (pt) |
| PH (1) | PH21623A (pt) |
| SE (1) | SE461703B (pt) |
| ZA (1) | ZA822120B (pt) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS604120A (ja) * | 1983-06-22 | 1985-01-10 | Shionogi & Co Ltd | 作用持続型ピナシジル製剤 |
| US4617311A (en) * | 1985-05-17 | 1986-10-14 | Eli Lilly And Company | Antiasthmatic method |
| EP3099304B1 (en) | 2014-01-31 | 2024-07-17 | Mayo Foundation for Medical Education and Research | Chroman derivatives and their use in the treatment of glaucoma |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1489879A (en) * | 1974-12-20 | 1977-10-26 | Leo Pharm Prod Ltd | N'-cyano-n'-3-pyridylguanidines |
-
1982
- 1982-03-23 IE IE676/82A patent/IE52935B1/en unknown
- 1982-03-25 GB GB8208778A patent/GB2098864B/en not_active Expired
- 1982-03-29 ZA ZA822120A patent/ZA822120B/xx unknown
- 1982-03-31 NZ NZ200185A patent/NZ200185A/en unknown
- 1982-03-31 US US06/363,934 patent/US4409222A/en not_active Expired - Fee Related
- 1982-04-07 NL NL8201493A patent/NL8201493A/nl not_active Application Discontinuation
- 1982-04-12 PH PH27117A patent/PH21623A/en unknown
- 1982-04-13 DE DE19823213579 patent/DE3213579A1/de active Granted
- 1982-04-14 IT IT20717/82A patent/IT1152106B/it active
- 1982-04-14 SE SE8202351A patent/SE461703B/sv not_active IP Right Cessation
- 1982-04-14 FR FR8206416A patent/FR2504008B1/fr not_active Expired
- 1982-04-14 CA CA000400957A patent/CA1172566A/en not_active Expired
- 1982-04-14 JP JP57063194A patent/JPS57197219A/ja active Granted
- 1982-04-15 AU AU82622/82A patent/AU550569B2/en not_active Expired
- 1982-04-15 BE BE0/207846A patent/BE892873A/fr not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| JPS57197219A (en) | 1982-12-03 |
| FR2504008A1 (fr) | 1982-10-22 |
| GB2098864B (en) | 1984-12-12 |
| FR2504008B1 (fr) | 1986-09-19 |
| DE3213579A1 (de) | 1982-11-04 |
| IT8220717A0 (it) | 1982-04-14 |
| BE892873A (fr) | 1982-10-15 |
| NZ200185A (en) | 1986-09-10 |
| CA1172566A (en) | 1984-08-14 |
| PH21623A (en) | 1987-12-11 |
| IE820676L (en) | 1982-10-15 |
| NL8201493A (nl) | 1982-11-01 |
| AU550569B2 (en) | 1986-03-27 |
| IE52935B1 (en) | 1988-04-13 |
| SE8202351L (sv) | 1982-10-16 |
| JPH0237326B2 (pt) | 1990-08-23 |
| US4409222A (en) | 1983-10-11 |
| DE3213579C2 (pt) | 1992-04-30 |
| ZA822120B (en) | 1983-03-30 |
| GB2098864A (en) | 1982-12-01 |
| AU8262282A (en) | 1983-05-12 |
| IT1152106B (it) | 1986-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100464693B1 (ko) | 5-메틸이소옥사졸-4-카복실산-(4-트리플루오로메틸)-아닐리드와n-(4-트리플루오로메틸페닐)-2-시아노-3-하이드록시크로톤산아미드와의배합물을함유하는제제 | |
| JPS591412A (ja) | 脳血管不全症処置用固形製剤 | |
| KR20030055257A (ko) | 두통, 편두통, 구역질 및 구토를 위한 약학적 조성물 | |
| EP0399051B1 (en) | Polyvalent antiinflammatory agent | |
| UA70299C2 (en) | Method for treatment of diabetes mellitus with rosmethod for treatment of diabetes mellitus with rosiglitazon and insulin iglitazon and insulin | |
| EP0005015B1 (en) | Use of a xanthine derivate in the manufacture of a medicament | |
| AU666992B2 (en) | Pharmaceutical composition for preventing or treating arteriosclerosis | |
| US4952410A (en) | Pharmaceutical products of moxonidine and hydrochlorothiazide | |
| SE461703B (sv) | Farmaceutiskt preparat foer behandling av hypertension eller kongestiv hjaertaakomma bestaaende av n-cyano-n-4-pyridyl-n -1,2,2-trimetylpropylguanidin och ett diuretikum | |
| JPH0825885B2 (ja) | 特発性血小板減少性紫斑病治療剤 | |
| HU206826B (en) | Pharmaceutical compositions containing 7-oxa-bicyclo-heptane-prostaglandine analogue for treating or preventing migrain | |
| KR900006993B1 (ko) | 아테롬성 동맥경화증 치료제로서의 dl-5-[(2-벤질-3,4-디하이드로-2H-벤조피란-6-일)메틸]티아졸리딘-2,4-디온 | |
| JPH07118148A (ja) | 肝癌予防剤 | |
| US3642987A (en) | Lincomycin and tetracycline compositions | |
| KR20010105418A (ko) | 기분 장애 치료용 오사네턴트 | |
| KR20010021796A (ko) | 선택성 세로토닌 재흡수 억제제 (ｓｓｒｉ)를 사용하는심장 질환의 치료 및 예방법 | |
| HU206623B (en) | Process for producing pharmaceutical compositions containing imidazo-pyrrolo-benzodiazepine as antipsychotic active component | |
| EP0567498A1 (en) | Pharmaceutical composition containing granisetron and dexamethasone | |
| JPH0349892B2 (pt) | ||
| HU181913B (en) | Process for preparing synergetic pharmaceutical composition with skeleton muscle relaxing activity | |
| JPH10338631A (ja) | 抗不安剤 | |
| JPS6317810B2 (pt) | ||
| US3538224A (en) | Composition for treating human mental disorders | |
| JPS6366285B2 (pt) | ||
| JPH0551565B2 (pt) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NAL | Patent in force |
Ref document number: 8202351-6 Format of ref document f/p: F |
|
| NUG | Patent has lapsed |
Ref document number: 8202351-6 Format of ref document f/p: F |